Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease

Clinical Neuropharmacology

Volumn 21, Issue 3, 1998, Pages 141-151

  Piercey, Montford F ^a  

^a PFIZER INC   (United States)

Author keywords

Adjunctive; Benzothiazole; Caudate; Monotherapy; Review; Substantia nigra

Indexed keywords

DOPAMINE 3 RECEPTOR; LEVODOPA; PRAMIPEXOLE;

DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; DRUG EFFECT; DRUG EFFICACY; DRUG RECEPTOR BINDING; GABAERGIC TRANSMISSION; HUMAN; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; PARKINSON DISEASE; PRIORITY JOURNAL; RECEPTOR AFFINITY; REVIEW;

EID: 0031864849     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (78)

1. Hornykiewicz O. The neurochemical basis of the pharmacology of Parkinson's disease. Handbook Exp Pharmacol 1989;88:185-204.
2. Cummings JL. Depression and Parkinson's disease: a review. Am J Psychiatry 1992;149:443-54.
3. Delong MF. Primate models of movement disorders of basal ganglia origin. Trends Neurosci 1990;13:281-5.
4. Olanow CW. Oxidation reactions in Parkinson's disease. Neurology 1990;40(suppl 3):32-9.
5. 3H]dopamine: impact of ascorbic acid and glutathione. J Neurochem 1994;63:1126-32.
6. Swerdlow RH, Parks JK, Miller SW, et al. Origin and functional consequences of the complex I defect in Parkinson's disease. Ann Neurol 1996;40:663-71.
7. Zamzani N, Susin SA, Marchettie P, et al. Mitochondrial control of nuclear apoptosis. J Exp Med 1996;183:1533-44.
8. Dolphin A.C. Nucleotide binding proteins in signal transduction and disease. Trends Neurosci 1987;10:53-7.
9. Civelli O, Buznow JR, Grandy KD. Molecular diversity of the dopamine receptors. Ann Rev Pharmacol Toxicol 1993;32:281-307.
10. 4 dopamine receptors determined in transfected cell lines. Clin Neuropharmacol 1995;18(suppl):S25-S33.
11. Kebabian JW, Calne DB. Multiple receptors for dopamine. Nature 1979;277:91-6.
12. 2 receptor mRNA. Brain Res 1991;564:203-19.
13. 4 with high affinity for the antipsychotic clozapine.Nature 1991;350:610-4.
14. Surmeir DJ, Song WJ, Yan Z. Coordinated expression of dopamine receptors in neostriatal medium spiny neurons. J Neurosci 1996;16: 6579-91.
15. 3 dopamine receptor: pharmacological properties and development of antibodies. J Pharmacol Exp Ther 1993;264:1002-11.
16. Carvey PM, Pieri S, Ling ZD. Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole. J Neural Transm 1997 (in press).
17. Fahn S. On-off phenomenon with levodopa therapy in parkinsonism: clinical and pharmacological correlation's and the effect of intramuscular pyridoxine. Neurology 1974;24:431-41.
18. Marsden CD, Parkes JD. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet 1977;i:345-9.
19. Rascol A, Monstastruc JL, Guiraud-Chaumeil B, Clanet M. BCT as the first treatment of Parkinson's disease: long-term results. Rev Neurol 1982;138:401-8.
20. Olanow CW. Single-blind double observer-controlled study of carbidopa/levodopa vs. BCT in untreated Parkinson patients. Arch Neurol 1988;45:206.
21. Rogawski MA, Aghajanian GK. Response of central monoaminergic neurons to lisuride: comparison with LSD. Life Sci 1979;24: 1289-98.
22. Gessa GL. Agonist and antagonist actions of lisuride on dopamine neurons: electrophysiological evidence. J Neural Transm 1988;S27: 201-10.
23. Bannon JJ, Grace AA, Bunney BS, Roth RH. Evidence for an irreversible interaction of bromocriptine with central dopamine receptors. Naunyn Schmiedebergs Arch Pharmacol 1980;312:37-1.
24. Scarnati E, Forchetti C, Ciancarelli G, Pacitti C, Agnoli A. Dopaminergic and non-dopaminergic neurons in substantia nigra: differential response to bromocriptine. J Neural Transm 1980;48:297-303.
25. Yarbrough GG, J McGuffin-Clineschmidt J, Singh DK, Haubrich DR, Bendesky RJ, Martin GE. Electrophysiological, biochemical, and behavioral assessment of dopamine autoreceptor activation by a series of dopamine agonists. Eur J Pharmacol 1984;99:73-8.
26. Rabey JM, Passeltiner P, Markey K, Asano T, Goldstein M. Stimulation of pre- and postsynaptic dopamine receptors by an ergoline and by a partial ergoline. Brain Res 1981;225:347-56.
27. 3-preferring dopamine agonist: comparison to other dopamine agonists. Eur J Pharmacol 1996;312:35-44.
28. Wachtel H. Antiparkinsonian dopamine agonists: a review of the pharmacokinetics and neuropharmacology in animals and humans. J Neural Transm Park Dis Dement Sect 1991;3:151-201.
29. Langston JW, Irwin I, Langston EB, Forno LS. Pargyline prevents MPTP-induced parkinsonism in primates. Science 1984;225: 1480-2.
30. Shoulson I, Fahn S, Oakes D, et al. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328:176-83.
31. 4 receptors. Eur J Pharmacol 1995;290:29-36.
32. Willner P, Lappas S, Cheeta S, Muscat R. Reversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexole. Psychopharmacology (Berl) 1994;115:454-62.
33. 3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons. Brain Res 1996;742:80-8.
34. 4. Neurosci Abstr 1994;20:526.
35. 3-preferring compound that lacks interactions with sigma binding sites. Neurosci Res Commun 1995;17:177-83.
36. 3 receptors. Br J Pharmacol 1993;110:93P.
37. 2 receptor stimulation of mitogenesis in transfected Chinese hamster ovary cells: relationship to dopamine stimulation of tyrosine phosphorylation. J Pharmacol Exp Ther 1993;267:1573-81.
38. 2 dopamine receptors. Mol Pharmacol 1994;45:51-60.
39. 3 receptors. Eur J Pharmacol 1994; 263:235-43.
40. 2 receptors. Neuroreport 1995;6:329-32.
41. 1 dopamine receptor activity of anti-parkinsonian drugs. Life Sci 1997;60:1597-603.
42. 3-receptor: a postsynaptic receptor inhibitory on rat locomotor activity. J Neural Transm 1993;94:11-9.
43. Meller E, Helmer-Matyjek E, Bohmaker K, et al. Receptor reserve at striatal dopamine autoreceptors: implications for selectivity of dopamine agonists. Eur J Pharmacol 1986;123:311-4.
44. Mierau J, Bechtel WD. SND 919 inhibits dopamine release in vivo and in vitro. Psychopharmacology (Berlin) 1988;96:338.
45. 2-receptor agonist. Eur J Pharmacol 1992;215:161-70.
46. 2-autoreceptor agonist, decreases the extracellular concentration of dopamine in vivo. Eur J Pharmacol 1991;200:65-72.
47. 2 receptor subtype dopamine agonist. Eur J Pharmacol 1996;317:29-38.
48. Maj J, Rogoz A, Skuza G, Kofodziejczyk. The behavioral effects of pramipexole, a novel dopamine receptor agonist. Eur J Pharmacol 1977;324:31-7.
49. 2 receptors in yawning and stereotypy in rats. Psychopharmacology (Berlin) 1990;100:141-4.
50. Yamada K, Matsumoto S, Nagashima M, Shirakawa K, Furukawa T. Potentiation of yawning response to the dopamine receptor agonists B-HT 920 and SND 919 by pindolol in the rat. J Neural Transm Gen Sect 1990;79:19-24.
51. Robertson GS, Tham C-S, Wilson C, Jakubovic A, Fibiger HC. In vivo comparisons of the effects of quinpirole and the putative presynaptic dopaminergic agonists B-HT 920 and SND 919 on striatal dopamine and acetylcholine release. J Pharmacol Exp Ther 1993;264:1344-51.
52. 3-preferring (Pramipexole) agonist in mice and rats. Neurosci Abstr 1994;20:827.
53. Svensson K, Eriksson E, Carlsson A. Partial dopamine receptor agonists reverse behavioral, biochemical and neuroendocrine effects of neuroleptics in the rat: potential treatment of extrapyramidal side effects. Neuropharmacology 1993;32:1037-45.
54. Domino EF, Ni Lisong, Zhang H, Kohno Y, Sasa M. Talipexole or pramipexole combinations with chloro-APB (SKF 82958) in MPTP-induced hemiparkinsonian monkeys. Eur J Pharmacol 1997;325:137-44.
55. 3-preferring dopamine agonist. Neuropsychopharmacology 1994;11: 266.
56. 3-preferring dopamine agonist. Neurosci Lett 1995;196:97-100.
57. 3 ligand, in rat striaturn. Neurosci Lett 1996;219:138-40.
58. 3 receptors. Brain Res 1997; 762:19-28.
59. Piercey MF, Hyslop DK, Hoffmann WE. Excitation of type II caudate neurons by systemic administration of dopamine agonists. Brain Res 1996;706:249-58.
60. Skirboll LR, Grace AA, Bunney BS. Dopamine auto- and postsynaptic receptors: electrophysiological evidence for differential sensitivity to dopamine agonists. Science 1979;206:80-2.
61. 2 dopamine receptor agonists on neurons in the rat caudate putamen: an electrophysiological study. J Neurosci 1988;8:4340-8.
62. Gerfen CR. The neostriatal mosaic: multiple levels of compartmental organization. Trends Neurosci 1992;15:133-9.
63. 3 receptor subtypes mediate excitatory and inhibitory responses respectively in rat SNPR. Neurosci Abstr 1996;22:219.
64. 3) as a target for neuroleptics. Nature 1990;347:146-51.
65. 3-preferring dopamine agonist. Neurosci Abstr 1995;21:1142.
66. Willner P, Muscat R, Papp M, Sampson D. Dopamine, depression and anti-depressant drugs. In: Willner P, Scheel-Kruger, editors. The mesolimbic dopamine system; from motivation to action. London: Wiley, 1991:3-15.
67. Wise RA, Rompre P-P. Brain dopamine and reward. Anna Rev Psychol 1989;40:191-225.
68. Maj J, Rogoz A, Skuza G, Kofodziejczyk. Antidepressant effects of pramipexole, a novel dopamine receptor agonist. J Neural Transm 1997;104:525-33.
69. Sethy VH, Wu H, Oostveen J, Hall ED. Neuroprotective effects of the dopamine agonists pramipexole and bromocriptine in 3-acetylpyridine-treated rats. Brain Res 1997;754:181-6.
70. 3 receptor. Neuroreport 1996;7:573-6.
71. Kitamura Y, Kohno Y, Nakaazawa M, Nomura Y. Inhibitory effects of talipexole and pramipexole on MPTP-induced dopamine reduction in the striatum of C57BL/6N mice. Jpn J Pharmacol 1997;74: 51-7.
72. Wright CE, Sisson TL, Ichhpurani AK, Peters GR. Steady-state pharmacokinetic properties of pramipexole in healthy volunteers. J Clin Pharmacol 1997;37:520-5.
73. Wynalda MA, Wenkers LC. Assessment of potential interactions between dopamine receptor agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen. Drug Metab Dispos 1997;25:1211-1214.
74. Hubble JP, Koller WC, Cutler NR, et al. Pramipexole in patients with early Parkinson's disease. Clin Neuropharmacol 1995;18:338-47.
75. Shannon KM, Bennet JP, Friedman JH. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. Neurology 1997;49:724-728.
76. Kieburtz K, Shoulson I, McDermott M, et al. A randomized doseranging study of the safety and efficacy of pramipexole in early Parkinson's disease. J Am Med Assoc 1997;278:125-130.
77. Lieberman A. Efficacy and safety of pramipexole in advance PD patients with the "wearing off" phenomenon, Neurology 1997;49: 162-168.
78. Kasper S, Bamas C, Heiden A et al. Pramipexole as adjunct to haloperidol in schizophrenia safety and efficacy. Eur Neuropsychol 1997;7:65-70.